NCT06302621 2026-01-15
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
Phase 1 Recruiting
Clinical Trials
7 trialsNCT06494189 2025-12-29
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
Phase 1 Completed
NCT07271446 2025-12-09
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
Precision Biotech Taiwan Corp.
Phase 1 Completed
NCT06897735 2025-11-18
EDDIS-a1
Petrov, Andrey
Phase 1 Not yet recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT02191891 2025-06-25
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 1 Completed
NCT01783587 2025-05-01
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed